Minimizing resistance consequences after virologic failure on initial combination therapy: A systematic overview

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 3, 2006, Pages 323-331

  Bartlett, John A ^a   Buda, Jeffrey J ^b   Von Scheele, Birgitta ^b   Mauskopf, Josephine A ^b   Davis, E Anne ^c   Elston, Robert ^d   King, Martin S ^e   Lanier, E Randall ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e ABBOTT LABORATORIES   (United States)

Author keywords

Antiretroviral naive; Antiretroviral therapy; First line therapy failure; Future drug options; HIV; Quantification of resistance; Resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; META ANALYSIS; MUTAGENESIS; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT FAILURE; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; META-ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33645100953     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000197070.69859.f3     Document Type: Review

References (40)

1. Centers for Disease Control and Prevention (CDC). U.S. HIV and AIDS cases reported through December 2001. HIV/AIDS Surveillance Report. 2002;13:7-30. Available at: http://www.cdc.gov/hiv/stats/hasr1302.pdf. Accessed 2003.
2. European Centre for Epidemological Monitoring of AIDS (EuroHIV). HIV/AIDS Surveillance in Europe End-Year Report 2002. Saint-Maurice: Institut de Veille Sanitaire. Available at: http://www.eurohiv.org/AidsSurv/Rapport_68/rapport_68. pdf. Accessed 2003.
3. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf. Accessed April 7, 2005.
4. EACS Euroguidelines Group. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS. 2003;17(Suppl2):S3-26.
5. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001;15:1369-1377.
6. Bartlett JA, Fath M, DeMasi R, et al. An updated meta-analysis of triple combination therapy in antiretroviral-naïve HIV-infected adults [abstract 586]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston.
7. Jiang H, Decks SG, Kuritzkes DR, et al. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003;188:1001-1008.
8. Johnson VA, Brun-Vezinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:215-221.
9. Johnson VA, Brun-Vézinet F, Clotet B, et al. International AIDS Society-USA drug resistance mutations group. Available at: http://hivinsite. ucsf.edu/pdf/md-04-01-97.pdf.
10. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. 2002;7:81-90.
11. Eron JJ Jr, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS. 2000;14:1601-1610.
12. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;18:775-779.
13. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
14. Maguire M, Gartland M, Moore S, et al. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS. 2000;14:1195-1201.
15. Gartland M. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antivir Ther. 2001;6:127-134.
16. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001;285:1155-1163.
17. Matheron S, Descamps D, Boue F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther. 2003;8:163-171.
18. Irlbeck D, Rouse E, Castillo S, et al. Treatment emergent mutations for previously naive HIV-infected adults failing ZDV + 3TC + EFZ and ABC + 3TC + EFV [abstract 11]. Presented at: 11th Conference on Retroviral Opportunistic Infections; 2004; San Francisco.
19. Ferrer E, Podzamczer D, Arnedo M, et al. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudrne plus nelfinavir or nevirapine. J Infect Dis. 2003;187:687-690.
20. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-937.
21. Raboud JM, Rae S, Vella S. Meta analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team. J Acquir Immune Defic Syndr. 1999;22(3): 260-266.
22. Conway B, Wainberg MA, Hall D, et al. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS. 2001;15:1269.
23. Squires KE, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS. 2000;14:1591-1600.
24. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-272.
25. Martinez-Picado J, Negredo E, Ruiz L, et al. Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med. 2003;139:81-89.
26. Gathe JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1 infected patients. AIDS. 2004;18:1529-1537.
27. Bartlett JA, Johnson J, Herrera G, et al. Initial therapy with abacavir + lamivudine (ABC = 3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS) [abstract TuPeB4544]. Presented at: XV International AIDS Conference; Bangkok, Thailand, 2004.
28. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-2303.
29. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304-2315.
30. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
31. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.
32. Bertz R, Chiu YL, Foit C, et al. Estimation of selective pressure by lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV) by examination of terminal-phase pharmacokinetics (PK) at steady-state [abstract 6.1]. Presented at: Fifth International Workshop on Clinical Pharmacology of HIV Therapy; 2004; Rome.
33. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224.
34. Lexiva package insert, GlaxoSmithKline, May 2004.
35. Borroto-Esoda K, Harris J, Waters J, et al. Baseline genotype as a predictor of virologie failure in patients receiving emtricitabine once daily or stavudine twice daily in combination with didanosine and efavirenz [abstract 672]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections (CROI), 2004; San Francisco.
36. Grover D, Allen L, Edwards SG, et al. Predictors of death, and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK. Antivir Ther. 2005;10(Suppl 1):57.
37. Hogg RS, Bangsberg D, Alexander C, et al. Drug resistance is associated with an increased risk of death in patients first starting HAART [abstract 712]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections (CROI), 2005; Boston.
38. Bennett D, McCormick L, Kline R, et al, and the HIV Drug Resistance ARVDRT/VARHS Surveillance Group. US surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera [abstract 674]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections (CROI), 2005; Boston.
39. Shet A, Mohri H, Berry L, et al. Transmission of drug resistant HIV-1 in patients with acute and early HIV-I infection in 2003 to 2004 [abstract 289]. Presented at: 12th Conference on Retroviruses and Opportunistic Infections (CROI), 2005; Boston.
40. Lack of resistance to boosted 908 confirmed through 48 weeks of therapy in naive subjects. [Abstract 558]. Presented at: the 2nd IAS Conference on HIV Pathogenesis and Treatment, 2003; Paris.